Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorXuzhou Medical University
About this trial
To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
Eligibility criteria
Qualifiers
All subjects must sign and date the Informed Consent before initiating any study specific procedures or activities;
At the age of 18-70 years old;
Diagnosed as relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (AML);
The patient has recovered from the toxicity of previous treatment;
Disqualifiers
Diagnosis of acute promyelocytic leukemia;
History or presence of a CNS disorder;
HBsAg is positive; HCV #HIV or Syphilis antibody are positive, CMV-DNA in peripheral blood is more than≥500 copies /mL;
History of severe hypersensitivity reaction;
Trial design
Treatments tested in this trial
- anti Tim-3/CD123 CAR-T cell therapy
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov